- Home
- VSTM vs PRTA Comparison
VSTM vs PRTA Comparison
Compare VSTM & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | PRTA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.7M | 482.3M |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VSTM | PRTA |
|---|---|---|
| Price | $5.96 | $9.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $14.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.6M | 363.4K |
| Earning Date | 05-18-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.87 | ★ 17.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,000,000.00 | $814,000.00 |
| Revenue This Year | $208.96 | $1,395.77 |
| Revenue Next Year | $269.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 285.21 | N/A |
| 52 Week Low | $4.01 | $4.32 |
| 52 Week High | $11.25 | $16.16 |
Technical Indicators
Market Signals| Indicator | VSTM | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 37.97 |
| Support Level | $5.65 | $8.80 |
| Resistance Level | $6.81 | $9.23 |
| Average True Range (ATR) | 0.39 | 0.51 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 20.71 | 13.24 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.